ClinicalTrials.gg
CompletedNCT02317627Updated May 26, 2022Results posted

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

A Phase 2 interventional study of KD025 in Psoriasis Vulgaris, sponsored by Kadmon Corporation, LLC. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
437th of 673
38 · median 77
Started
2014
with 38 others
Phase 2
200 of 764
5 open now
Registered
333rd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 437th largest by enrollment of the 673 interventional ones that give a count, is one of 39 that started in 2014, is one of 200 in phase 2, and was the 333rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one line of systemic therapy.

Read the detailed description

Study KD025-206 was a phase 2, open-label, dose-finding, safety, tolerability, activity, and PK study of KD025 in subjects with psoriasis who had failed at least 1 line of systemic therapy or phototherapy.

Subjects received KD025 PO for 12 weeks. Planned enrollment was 36 subjects in 3 cohorts, 12 subjects per cohort:

  • Cohort 1 (12 subjects): KD025 400 mg once daily (QD) PO for 12 weeks
  • Cohort 2 (12 subjects): KD025 200 mg PO twice daily (BID) for 12 weeks
  • Cohort 3 (12 subjects): KD025 400 mg BID PO for 12 weeks

Subjects were initially enrolled simultaneously in Cohort 1 and Cohort 2 according to a randomization schedule, with safety reviewed before any subjects. If safety guidelines were met, Cohort 3 was added to explore the efficacy and safety of KD025 at a dose of 400 mg PO BID.

Subjects underwent safety evaluations: medical history evaluations; physical examinations (PEs); vital sign measurements; weight measurements; adverse event (AE) assessments; concomitant medication assessments; blood sample collection for hematology, chemistry, and coagulation; lipid panel; thyroid-stimulating hormone; measurements of antinuclear antibody; anti-double-stranded deoxyribonucleic acid; Complement C; antiphospholipid antibody; liver ultrasound (US); pregnancy testing for females of childbearing potential; PK sampling (subset of subjects only); urinalysis; and electrocardiogram (ECG).

Subjects underwent efficacy evaluations: Psoriasis Area and Severity Index (PASI) scoring; Physicians Global Assessment (PGA) scoring; and Dermatologic Life Quality Index (DLQI) scoring.

Subjects participating in PK sampling were admitted to the clinic on Month 1 Day 1 (M1D1) for PK procedures and were discharged on M2D2. Blood samples for PK analyses were collected on M2D1 and Month 3 Day 1 (M3D1) on an outpatient basis. Subjects were not to take their morning dose until after blood samples were drawn.

A Follow-Up visit occurred 30 ± 3 days after the last dose of study drug.

The endpoints for efficacy were PASI, PGA, and DSQI scores.

  1. Psoriasis Area and Severity Index (PASI): The PASI is a measure of the psoriasis disease severity using the average redness, thickness, and scaliness of the lesions (each graded on a 0 to 4 scale), which is weighted by the area of involvement. The PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 (no disease) to 72 (maximal disease).
  2. Physicians Global Assessment (PGA): The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.
  3. Dermatology Life Quality Index (DLQI): The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life (QOL). It is a 10-item questionnaire that assesses 6 different aspects of quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Possible DLQI scores range from 0 (no detectable impairment on a subject's QOL) to 30 (extremely large effect on a subject's QOL).

Safety was assessed by standard clinical and laboratory tests (hematology, serum chemistry, and urinalysis), PEs, and reporting of treatment-emergent adverse events (TEAEs). Toxicity grades were defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In addition, subjects had liver ultrasound and liver functioning testing assessed for possible steatosis.

Blood samples for determination of PK plasma concentrations of KD025 and its metabolites were collected for maximum concentration (Cmax); time of maximum concentration (Tmax); area under the concentration-time curve (AUC) at 0 to 24 hours, 0 to last, and 0 to infinity (0 to 24, 0 to last, 0 to infinity [inf]); half-life (t1/2); and accumulation ratio (metabolic-to-parent drug ratio).

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written prior to the performance of any study specific procedures
  • Diagnosis of moderately severe plaque psoriasis that has been moderately stable for 6 months and failed at least 1 line of systemic or phototherapy and is a candidate for additional systemic therapy
  • PASI of ≥ 12 within the 24-hour period prior to the first dose of study drug
  • At least 10% of body surface area affected by plaque psoriasis within the 24-hour period prior to the first dose of study drug
  • Willing to avoid tanning devices
  • Willing to forgo other systemic and topical treatments for psoriasis during the course of the study
  • Adequate bone marrow function: > 1500/mm\^3; > 9.0 g/dL; > 100,000/mm\^3
  • Negative urine pregnancy test (for women of ) documented within the 24-hour period prior to the first dose of study drug
  • Agree to use a highly effective method of (\< 1% per year failure rate) during the study and for 1 month after the termination of the study. Effective birth control included implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, or vasectomized partner
  • Willing to complete all study measurements and assessments in compliance with the protocol

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug-induced (antimalarials, lithium) psoriasis (If subject is taking angiotensin II receptor blockers or beta blockers doses had to be stable for 6 months prior to study entry)
  • Use of or therapy within 4 weeks prior to study entry except for Class 5 or weaker topical corticosteroids or immunosuppressive therapies to the face, groin, or scalp.
  • Use of methotrexate, acitretin, or cyclosporine within 4 weeks prior to study entry
  • Use of phototherapy within 4 weeks prior to study entry
  • Use of biologic therapies, including antibodies to IL-17, within 3 months prior to study entry
  • Concomitant condition requiring treatment with moderate to high dose steroids in the 12 weeks prior to screening
  • Viral, fungal, or bacterial skin infection
  • Pregnant or lactating
  • History of gastrointestinal (GI) surgery including bariatric surgery, or any GI condition that might interfere with drug absorption
  • Currently participating in another study with an drug or within 28 days of study entry
  • History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease or coronary artery disease)
  • Regular and excessive use of alcohol within the 2 years prior to study entry defined as alcohol intake > 14 drinks per week in a man or > 7 drinks per week in a woman. Approximately 10 g of alcohol equals one "drink" unit. One unit equals 1 ounce of distilled spirits, one 12-ounce beer, or one 4-ounce glass of wine
  • History or presence of any of the following:

    1. (ALT) or aspartate aminotransferase (AST) > 2.0 × the (ULN) at screening. (Subjects with an isolated AST elevation of any magnitude, or a ratio of AST:ALT > 1.5 interviewed regarding use of alcohol, have levels repeated and participation in the study should be discussed with the medical monitor.)
    2. Renal disease and/or serum creatinine > 1.5 × ULN at screening
  • (F) interval (QT interval data corrected using Fridericia's formula) > 450 msec at the screening or predose
  • Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Cohort 1

    KD025 400 mg QD PO for 12 weeks

    Drug: KD025

  • Experimental
    Cohort 2

    KD025 200 mg BID PO for 12 weeks

    Drug: KD025

  • Experimental
    Cohort 3

    KD025 400 mg BID PO for 12 weeks

    Drug: KD025

Interventions

  • DrugKD025

    Also known as: SLx-2119, belumosudil

06

What researchers measure

Primary outcomes

  1. Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population

    Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 12 weeks

  2. Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population

    Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 12 weeks

  3. Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population

    Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.

    Time frame: 12 weeks

Secondary outcomes

  1. Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population

    Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

    Time frame: 12 weeks

  2. Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population

    Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

    Time frame: 12 weeks

  3. Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population

    The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 4 weeks

  4. Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population

    The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 8 weeks

  5. Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population

    The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 12 weeks

  6. Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population

    The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 12 weeks

  7. Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population

    Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

    Time frame: 4 weeks

  8. Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population

    Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

    Time frame: 8 weeks

  9. Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population

    Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

    Time frame: 8 weeks

  10. Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population

    Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement

    Time frame: 4 weeks

  11. Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population

    Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement

    Time frame: 8 weeks

  12. Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population

    Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement

    Time frame: 12 weeks

  13. Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population

    Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.

    Time frame: 12 weeks

  14. Efficacy: Mean Changes in DLQI at EOT--ITT Population

    Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable

    Time frame: 12 weeks

  15. Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population

    Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable.

    Time frame: 12 weeks

  16. Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2

    Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)

    Time frame: 24 hours

  17. Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2

    Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2): AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time "t" post-dose

    Time frame: 24 hours

  18. Pharmacokinetics: t(1/2) of KD025

    Half-life (t\[1/2\]) of Parent drug (KD025)

    Time frame: 24 hours

  19. Pharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2

    Metabolite-to-parent ratio of maximum concentration (MR C\[max\]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time "t" for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)

    Time frame: 24 hours

07

Results

Posted Nov 1, 2021

Participant flow

Participant flow — Overall Study
Milestone400 mg QD200 mg BID400 mg BID
Started131312
Completed1188
Not completed254
Withdrew: Withdrawal by subject011
Withdrew: Lost to follow-up200
Withdrew: Stopped by investigator010
Withdrew: Adverse event023
Withdrew: Non-compliance with study drug010

Outcome measures

PrimaryEfficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population

Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
12 weeks
Reported as:
Number · Percentage of participants (%)
Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
≥ 75% Reduction from Baseline16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)9.1 (0.2 to 41.3)11.4 (3.2 to 26.7)
≥ 50% Reduction from Baseline41.7 (15.2 to 72.3)50.0 (21.1 to 78.9)18.2 (2.3 to 51.8)37.1 (21.5 to 55.1)
PrimaryEfficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population

Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
12 weeks
Reported as:
Number · Percentage of participants (%)
Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
≥ 75% Reduction from Baseline16.7 (2.1 to 48.4)14.3 (0.4 to 57.9)14.3 (0.4 to 57.9)15.4 (4.4 to 34.9)
≥ 50% Reduction from Baseline41.7 (15.2 to 72.3)71.4 (29.0 to 96.3)28.6 (3.7 to 71.0)46.2 (26.6 to 66.6)
PrimarySafety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population

Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants (%)
Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
All AEs1211831
Grade 1 (Mild)69.246.233.350.0
Grade 2 (Moderate)69.246.250.055.3
Grade 3 (Severe)7.77.78.37.9
Grade 4 (Life-threatening)7.7002.6
Grade 5 (Death)0000
Related to KD02538.523.158.339.5
Grade 3, 4, or 5 Related to KD02507.702.6
SecondaryEfficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population

Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

Time frame:
12 weeks
Reported as:
Mean · Score on a scale
Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
End of Treatment (or 12 Weeks)12.4 (7.9 to 17.0)10.3 (7.0 to 13.6)14.4 (8.8 to 19.9)12.3 (9.9 to 14.7)
Change from Baseline at End of Treatment-8.8 (-16.5 to -1.1)-6.0 (-9.5 to -2.4)-4.8 (-8.9 to -0.7)-6.6 (-9.5 to -3.7)
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.0282 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.0035 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.0261 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = < 0.0001 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryEfficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population

Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

Time frame:
12 weeks
Reported as:
Mean · Score on a scale
Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
12 Weeks12.4 (7.9 to 17.0)7.6 (5.6 to 9.6)15.5 (5.8 to 25.1)12.0 (8.9 to 15.0)
Change from Baseline at 12 Weeks-8.8 (-16.5 to -1.1)-7.9 (-11.9 to -3.9)-5.9 (-12.5 to 0.7)-7.8 (-11.4 to -4.1)
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.0282 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.0029 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.0703 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = 0.0002 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryEfficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population

The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
4 weeks
Reported as:
Number · Percentage of participants (%)
Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population76.9 (46.2 to 95.0)66.7 (34.9 to 90.1)58.3 (27.7 to 84.8)67.6 (50.2 to 82.0)
SecondaryEfficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population

The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
8 weeks
Reported as:
Number · Percentage of participants (%)
Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population83.3 (51.6 to 97.9)100 (66.4 to 100)85.7 (42.1 to 99.6)89.3 (71.8 to 97.7)
SecondaryEfficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population

The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
12 weeks
Reported as:
Number · Percentage of participants (%)
Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population75.0 (42.8 to 94.5)75.0 (42.8 to 94.5)81.8 (48.2 to 97.7)77.1 (59.9 to 89.6)
SecondaryEfficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population

The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
12 weeks
Reported as:
Number · Percentage of participants (%)
Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population
Percentage of participants (%)400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
4 Weeks75.0 (42.8 to 94.5)85.7 (42.1 to 99.6)71.4 (29.0 to 96.3)76.9 (56.4 to 91.0)
8 Weeks83.3 (51.6 to 97.9)100 (59.0 to 100)85.7 (42.1 to 99.6)88.5 (69.8 to 97.6)
12 Weeks75.0 (42.8 to 94.5)100 (59.0 to 100)85.7 (42.1 to 99.6)84.6 (65.1 to 95.6)
SecondaryEfficacy: Mean Change in PASI Score After 4 Weeks---ITT Population

Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

Time frame:
4 weeks
Reported as:
Number · Score on a scale
Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population-4.7 (-7.8 to -1.6)-2.6 (-5.3 to 0)-2.3 (-5.5 to 1.0)-3.2 (-4.8 to -1.6)
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.0064 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.0479 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.1513 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = 0.0002 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryEfficacy: Mean Change in PASI Score After 8 Weeks---ITT Population

Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

Time frame:
8 weeks
Reported as:
Number · Score on a scale
Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population-8.6 (-15.0 to -2.1)-6.4 (-9.6 to -3.2)-4.7 (-10.0 to 0.6)-6.9 (-9.8 to -4.0)
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.0137 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.0017 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.0743 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = < 0.0001 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryEfficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population

Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population. \[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\] Negative mean change is favorable; positive mean change is unfavorable

Time frame:
8 weeks
Reported as:
Number · Score on a scale
Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
4 Weeks-4.4 (-7.8 to -1.1)-3.5 (-7.2 to 0.2)-2.7 (-8.1 to 2.7)-3.7 (-5.7 to -1.7)
8 Weeks-8.6 (-15.0 to -2.1)-6.8 (-10.9 to -2.7)-4.7 (-10.0 to 0.6)-7.1 (-10.2 to -3.9)
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.0140 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.0620 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.2620 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = 0.0008 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg QD · t-test, 2 sided · p = 0.0137 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.0064 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.0743 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = < 0.0001 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryEfficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population

Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population
Percentage of participants400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Clear/Excellent (75% to 100% Improvement)0000
Good (50% to 74% Improvement)7.78.38.38.1
Fair (25% to 49% Improvement)46.258.341.748.6
SecondaryEfficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population

Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population
Percentage of participants400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Clear/Excellent (75% to 100% Improvement)8.3003.6
Good (50% to 74% Improvement)25.011.114.317.9
Fair (25% to 49% Improvement)25.088.942.950.0
SecondaryEfficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population

Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population
Percentage of participants400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Clear/Excellent (75% to 100% Improvement)0000
Good (50% to 74% Improvement)33.325.018.225.7
Fair (25% to 49% Improvement)33.350.036.440.0
SecondaryEfficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population

Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population. The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse. PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population
Percentage of participants400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
4 Weeks: Clear/Excellent0000
4 Weeks: Good8.3014.37.7
4 Weeks: Fair41.785.742.953.8
8 Weeks: Clear/Excellent8.3003.8
8 Weeks: Good25.0014.315.4
8 Weeks: Fair25.010042.950.0
12 Weeks: Clear/Excellent0000
12 Weeks: Good33.314.328.626.9
12 Weeks: Fair33.385.728.646.2
SecondaryEfficacy: Mean Changes in DLQI at EOT--ITT Population

Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable

Time frame:
12 weeks
Reported as:
Mean · Score on a scale
Efficacy: Mean Changes in DLQI at EOT--ITT Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Mean Changes in DLQI at EOT--ITT Population-4.9 ± 4.68-5.1 ± 5.35-2.5 ± 4.50-4.2 ± 4.86
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.004 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.007 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.090 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = < 0.001 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryEfficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population

Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population. \[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.\] Negative mean change is favorable; positive mean change is unfavorable.

Time frame:
12 weeks
Reported as:
Mean · Score on a scale
Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population
Score on a scale400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population-4.9 ± 4.68-6.3 ± 5.82-2.3 ± 2.93-4.6 ± 4.71
Statistical analysis
  • 400 mg QD · t-test, 2 sided · p = 0.004 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 200 mg BID · t-test, 2 sided · p = 0.029 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • 400 mg BID · t-test, 2 sided · p = 0.084 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
  • Overall (All Subjects) · t-test, 2 sided · p = < 0.001 (Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.)
SecondaryPharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2

Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)

Time frame:
24 hours
Reported as:
Mean · ng/mL
Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2
ng/mL400 mg QD200 mg BID
KD0253140 ± 17601770 ± 1190
KD025m123.2 ± 9.6622.8 ± 15.3
KD025m2632 ± 278203 ± 204
SecondaryPharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2

Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2): AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time "t" post-dose

Time frame:
24 hours
Reported as:
Mean · hour*ng/mL
Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2
hour*ng/mL400 mg QD200 mg BID
KD025: AUC(0-12)16200 ± 89109150 ± 5950
KD025m2: AUC(0-12)2300 ± 907757 ± 823
KD025: AUC(0-24)18800 ± 1060021800 ± 13900
KD025m2: AUC(0-24)2510 ± 11801790 ± 1850
KD025: AUC(0-t)18800 ± 1060025100 ± 14800
KD025m1: AUC(0-t)93.4 ± 18.1250 ± 0
KD025m2: AUC(0-t)2550 ± 10801960 ± 1950
SecondaryPharmacokinetics: t(1/2) of KD025

Half-life (t\[1/2\]) of Parent drug (KD025)

Time frame:
24 hours
Reported as:
Mean · Hours
Pharmacokinetics: t(1/2) of KD025
Hours400 mg QD200 mg BID
Pharmacokinetics: t(1/2) of KD0258.00 ± 2.475.13 ± 1.12
SecondaryPharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2

Metabolite-to-parent ratio of maximum concentration (MR C\[max\]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time "t" for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)

Time frame:
24 hours
Reported as:
Mean · Number (ratio)
Pharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2
Number (ratio)400 mg QD200 mg BID
KD025m1: MR C(max)0.00736 ± 0.002720.00984 ± 0.00287
KD025m2: MR C(max)0.199 ± 0.07940.101 ± 0.0469
KD025m1: MR AUC(0-t)0.00458 ± 0.002530.00577 ± 0
KD025m2: MR AUC(0-t)0.133 ± 0.04490.0719 ± 0.0336

Adverse events

Collected over Screening Period ≤ 4 week Screening Period + 12-week Treatment Period + 30-day Follow-up = Up to 20 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 mg QD0/13 (0%)0/13 (0%)12/13 (92.3%)
200 mg BID0/13 (0%)0/13 (0%)11/13 (84.6%)
400 mg BID0/12 (0%)0/12 (0%)8/12 (66.7%)
Overall (All Subjects)0/38 (0%)0/38 (0%)31/38 (81.6%)
Most frequent other events
Showing 10 of 57
Most frequent other events
Event400 mg QD200 mg BID400 mg BIDOverall (All Subjects)
Alanine aminotransaminase (ALT) increasedInvestigations1/130/134/125/38
Aspartate aminotransferase (AST) increasedInvestigations1/130/132/123/38
Upper respiratory tract infectionInfections and infestations0/130/132/122/38
DiarrheaGastrointestinal disorders2/130/131/123/38
NauseaGastrointestinal disorders0/132/131/123/38
VomitingGastrointestinal disorders1/132/130/123/38
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/132/130/122/38
Liver function test abnormalInvestigations1/131/131/123/38
Back painMusculoskeletal and connective tissue disorders1/130/131/122/38
PruritusSkin and subcutaneous tissue disorders1/130/131/122/38

Baseline characteristics

Intent-to-Treat (ITT) defined as all subjects enrolled in the study

Age, Continuous
Age, Continuous(years)400 mg QD200 mg BID400 mg BIDTotal
Mean44.6 ± 10.3246.5 ± 11.9250.5 ± 10.2647.1 ± 10.86
Age, Continuous
Age, Continuous(years)400 mg QD200 mg BID400 mg BIDTotal
Median46.0 (29 to 60)45.0 (25 to 67)54.5 (30 to 64)47.5 (25 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)400 mg QD200 mg BID400 mg BIDTotal
Female56415
Male87823
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)400 mg QD200 mg BID400 mg BIDTotal
Hispanic or Latino54615
Not Hispanic or Latino89623
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)400 mg QD200 mg BID400 mg BIDTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White11121235
More than one race0000
Unknown or Not Reported0000
BMI (body mass index)--Mean
BMI (body mass index)--Mean(kg/m^2)400 mg QD200 mg BID400 mg BIDTotal
Mean34.42 ± 7.13232.81 ± 7.74732.65 ± 10.58233.31 ± 8.362
BMI--Median
BMI--Median(kg/m^2)400 mg QD200 mg BID400 mg BIDTotal
Median35.70 (22.2 to 45.4)31.40 (23.4 to 51.4)30.35 (22.7 to 63.8)31.50 (22.2 to 63.8)
Psoriasis Area and Severity Index (PASI) Score--Mean
Psoriasis Area and Severity Index (PASI) Score--Mean(Units on a scale)400 mg QD200 mg BID400 mg BIDTotal
Mean21.0 ± 10.8518.3 ± 8.5120.3 ± 7.2419.8 ± 8.87

4 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Arrowhead Health Centers
    Glendale, Arizona 85306, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Shondra L. Smith
    Lake Charles, Louisiana 70605, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Clinical Studies Group, LLC
    Henderson, Nevada 89074, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • High Point Clinical Trials Center
    High Point, North Carolina 27265, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Metroplex Clinical Research Center (MCRC)
    Dallas, Texas 75231, United States
09

References and documents

Publications

  • Zanin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, Arencibia C, Polimera S, Schueller O, Fuentes-Duculan J, Bonifacio KM, Kunjravia N, Cueto I, Soung J, Fleischmann RM, Kivitz A, Lebwohl M, Nunez M, Woodson J, Smith SL, West RF, Berger M, Krueger JG, Ryan JL, Waksal SD. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol. 2017 May 15;198(10):3809-3814. doi: 10.4049/jimmunol.1602142. Epub 2017 Apr 7. PubMed 28389592 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2021, 5 years 8 months after primary completion. A results delay was requested in Apr 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2014
First posted
Dec 16, 2014
Start
Dec 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results delay requested
Apr 6, 2016
Results first posted
Nov 1, 2021
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02317627
Responsible party
Sponsor
First posted
Dec 16, 2014
Start date
Dec 2014
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Nov 1, 2021
Last update
May 26, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion